How high a dose of stimulant medication in adult attention deficit hyperactivity disorder?

References

• Sachdev P. Attention deficit hyperactivity disorder in adults. Psychological Medicine 1999; 29: 507–514
   PubMed Web of Science ®Google Scholar
• Biederman J. A 55‐year‐old man with attention‐deficit/hyperactivity disorder. Journal of the American Medical Association 1998; 280: 1086–1092
   PubMed Web of Science ®Google Scholar
• Spencer T, Biederman J, Wilens T, Faraone SV. Is attention‐deficit hyperactivity disorder in adults a valid disorder?. Harvard Review of Psychiatry 1994; 1: 326–335
   PubMed Web of Science ®Google Scholar
• Biedernam J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition and psychosocial functioning in adults with attention deficit hyperactivity disorder. American Journal of Psychiatry 1993; 150: 1792–1798
   PubMedGoogle Scholar
• Wilens TE, Biederman J, Spencer TJ, Prince J. Pharmacotherapy of adult attention deficit hyperactivity disorder: a review. Journal of Clinical Psychopharmacology 1995; 15: 270–279
   PubMed Web of Science ®Google Scholar
• Wood DR, Reimherr FW, Wender PH, Johnson GE. Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. Archives of General Psychiatry 1976; 33: 1453–1460
   PubMed Web of Science ®Google Scholar
• Wender PH, Reimherr FW, Wood DR. Attention deficit disorder (minimal brain dysfunction) in adults: a replication study of diagnosis and drug treatment. Archives of General Psychiatry 1981; 142: 547–552
   Google Scholar
• Mattes JA, Boswell L, Oliver H. Methylphenidate effects on symptoms of attention deficit disorder in adults. Archives of General Psychiatry 1984; 41: 1059–1063
   PubMed Web of Science ®Google Scholar
• Gualtieri CT, Ondrusek MG, Finley C. Attention deficit disorder in adults. Clinical Neuropharmacology 1985; 8: 343–356
   PubMed Web of Science ®Google Scholar
• Spencer T, Wilens TE, Biederman J, Faraone SV, Ablon S, Lapsley K. A double blind, crossover comparison of methylphenidate and placebo in adults with childhood onset attention deficit hyperactivity disorder. Archives of General Psychiatry 1995; 52: 434–443
   PubMed Web of Science ®Google Scholar
• Kessler S. Drug therapy in attention‐deficit hyperactivity disorder. Southern Medical Journal 1996; 89: 33–38
   PubMed Web of Science ®Google Scholar
• Block RW. Medication for attention‐deficit hyperactivity disorder. Southern Medical Journal 1996; 89: 95–96
   PubMedGoogle Scholar
• Paterson R, Douglas C, Hallmayer J, Hagan M, Krupenia Z. A randomised, double‐blind, placebo‐controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Australian and New Zealand Journal of Psychiatry 1999; 33: 494–502
   PubMed Web of Science ®Google Scholar
• Wender PH. Attention‐deficit hyperactivity disorder in adults. Oxford University Press, New York 1995
   Google Scholar
• Dulcan M. AACAP Guidelines. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention‐deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 1997; 36(Suppl. 10S)85S–121S
   PubMedGoogle Scholar
• Hornykiewicz O. Dopamine (3‐hydroxytyramine) and brain function. Pharmacological Reviews 1966; 18: 925–964
   PubMed Web of Science ®Google Scholar
• Boissier JR, Simon P. On the potentiation of DOPA effects by monoamine oxidase inhibitors. Psychopharmacologia 1966; 8: 428–436, in French
   PubMedGoogle Scholar
• Helmeste DM, Seeman P. Amphetamine‐induced hyperlocomotion in mice with more brain D2 dopamine receptors. Psychiatry Research 1982; 7: 351–359
   PubMedGoogle Scholar
• Steiner NO, Delay ER, Isaac W. Effects of drugs, age and illumination on response speed of squirrel monkeys. Pharmacology Biochemistry and Behavior 1986; 24: 503–506
   PubMedGoogle Scholar
• Luthman J, Fredriksson A, Lewander T, Jonsson G, Archer T. Effects of D‐amphetamine and methylphenidate on hyperactivity by neonatal 6‐hydroxydopamine treatment. Psychopharmacology 1989; 99: 550–557
   PubMedGoogle Scholar
• Seeman P, Madras BK. Anti‐hyperactivity medication: methylphenidate and amphetamine. Molecular Psychiatry 1998; 3: 386–396
   PubMed Web of Science ®Google Scholar
• Parsons LH, Justice JB, Jr. Extracellular concentration and in vivo recovery of dopamine in the nucleus accumbens using microdialysis. Journal of Neurochemistry 1992; 58: 212–218
   PubMed Web of Science ®Google Scholar
• Wall SC, Gu H, Rudnick G. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Molecular Pharmacology 1995; 47: 544–550
   PubMed Web of Science ®Google Scholar
• Sharp T, Zetterström T, Ljungberg T, Ungerstedt U. A direct comparison of amphetamine‐induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Research 1987; 401: 322–330
   PubMed Web of Science ®Google Scholar
• Kuczenski R, Segal D. Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. Journal of Neuroscience 1989; 9: 2051–2086
   PubMedGoogle Scholar
• Gonon FG. Non‐linear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience 1988; 24: 19
   PubMed Web of Science ®Google Scholar
• Volkow ND, Ding Y‐S, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in human brain. Archives of General Psychiatry 1995; 52: 456–463
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang G‐J, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral mehtylphenidate. American Journal of Psychiatry 1998; 155: 1325–1331
   PubMed Web of Science ®Google Scholar
• Ginovart N, Farde L, Halldin C, Swahn CG. Changes in striatal D2‐receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates. Synapse 1999; 31: 154–162
   PubMed Web of Science ®Google Scholar
• Persico AM, Schindler CW, O'Hara BF, Brannock MT, Uhl GR. Brain transcription factor expression ‐ effects of acute and chronic amphetamine and injection stress. Brain Research Molecular Brain Research 1993; 20: 91–100
   PubMedGoogle Scholar
• Segal DS, Kuczenski R. An escalating dose binge model of amphetamine psychosis ‐ behavioural and neurochemical characteristics. Journal of Neuroscience 1997; 17: 2551–2566
   PubMed Web of Science ®Google Scholar
• Gillberg C, Melander H, von Knorring A‐L, et al. Long‐term stimulant treatment of children with attention‐deficit hyperactivity disorder symptoms: a randomized, double‐blind, placebo‐controlled trial. Archives of General Psychiatry 1997; 54: 857–864
   PubMed Web of Science ®Google Scholar
• Seeman P. Brain dopamine receptors. Pharmacology Review 1980; 32: 229–313
   PubMed Web of Science ®Google Scholar
• Patrick KS, Markowitz JS. Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention‐deficit hyperactivity disorder. Human Psychopharmacology 1997; 12: 527–546
   Web of Science ®Google Scholar
• Gualtieri CT, Wargin W, Kanoy R, et al. Clinical studies of methylphenidate serum levels in children and adults. Journal of the American Academy of Child Psychiatry 1982; 21: 19–26
   PubMedGoogle Scholar
• Angrist B, Corwin J, Bartlik B, Cooper T. Early pharmacokinetics and clinical effects of oral d‐amphetamine in normal subjects. Biological Psychiatry 1987; 22: 11357–11368
   Google Scholar
• Wargin W, Patrick K, Kilts C, et al. Pharmacokinetics of methylphenidate in man, rat and monkey. Journal of Pharmacology and Experimental Therapeutics 1983; 226: 382–386
   PubMed Web of Science ®Google Scholar
• Aoyama T, Sasaki T, Kotaki H, et al. Pharmacokinetics and pharmacodynamics of (+) ‐threo‐methylphenidate enantiomer in patients with hypersomnia. Clinical Pharmacology and Therapeutics 1994; 55: 270–276
   PubMed Web of Science ®Google Scholar
• Aoyama T, Kotaki H, Sasaki T, Sawada Y, Honda Y, Iga T. Nonlinear kinetics of threo‐methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers. European Journal of Clinical Pharmacology 1993; 44: 79–84
   PubMed Web of Science ®Google Scholar
• Shader RI, Harmatz JS, Oesterheld JR, Parmelee DX, Sallee FR, Greenblatt DJ. Population pharmacokinetics of methylphenidate in children with attention‐deficit hyperactivity disorder. Journal of Clinical Pharmacology 1999; 39: 775–785
   PubMed Web of Science ®Google Scholar
• Hungund BL, Perel JM, Hurwic MJ, Sverd J, Winsberg BG. Pharmacokinetics of methylphenidate in hyperkinetic children. British Journal of Clinical Pharmacology 1979; 8: 571–576
   PubMed Web of Science ®Google Scholar
• Birmaher B, Greenhill LL, Cooper TB, Fried J, Maminski B. Sustained release methylphenidate: pharmacokinetic studies in ADDH males. Journal of the American Academy of Child and Adolescent Psychiatry 1989; 28: 768–772
   PubMed Web of Science ®Google Scholar
• Wilens TE, Biederman J. The stimulants. Psychiatric clinics of North America, D Schaffer. W.B. Saunders, Philadelphia 1992; 191–222
   Google Scholar
• Levy F. Side effects of stimulant use. Journal of Paediatrics and Child Health 1993; 29: 250–254
   PubMed Web of Science ®Google Scholar
• Castellanos FX. Stimulants and tic disorders: from dogma to data [commentary]. Archives of General Psychiatry 1999; 56: 337–338
   PubMedGoogle Scholar
• Connell PH. Amphetamine psychosis. Oxford University Press, London 1958, Maudsley Monograph No 5
   Google Scholar
• Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attention deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999; 104: 293–294
   Google Scholar
• Garland EJ. Intranasal abuse of precribed methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry 1998; 37: 573–574
   PubMed Web of Science ®Google Scholar
• Jaffe SL. Intranasal abuse of prescribed methylphenidate by an alcohol and drug abusing adolescent with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 1991; 30: 774–775
   Google Scholar
• Parran TV, Jasinski DR. Intravenous methylphenidate abuse: prototype for prescription drug abuse. Archives of Internal Medicine 1991; 151: 781–783
   PubMed Web of Science ®Google Scholar
• Goyer PF, Davis GC, Rapoport JL. Abuse of prescribed stimulant medication by a 13‐year‐old hyperactive boy. Journal of the American Academy of Child Psychiatry 1979; 18: 170–175
   PubMedGoogle Scholar
• Volkow ND, Wang G‐J, Fowler JS, et al. Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self‐reports of ‘high’. Journal of Pharmacology and Experimental Therapeutics 1999; 228: 14–20
   Google Scholar
• Angrist B. Amphetamine psychosis: clinical variations of the syndrome. Amphetamine and its analogs: psychopharmacology, toxicology, and abuse, AK Cho, DS Segal. Academic Press, San Diego 1994; 387–414
   Google Scholar
• Ridley RM, Baker HF, Owen F, Cross AJ, Crow TJ. Behavioral and biochemical effects of chronic amphetamine treatment in the vervet monkey. Psychopharmacology 1982; 78: 245–251
   PubMedGoogle Scholar
• Ellison G, Morris W. Opposed stages of continuous amphetamine administration: parallel alterations in motor stereotypies and in vivo spiroperidol accumulation. European Journal of Pharmacology 1981; 74: 207–214
   PubMedGoogle Scholar
• Castner SA, Goldman‐Rakic PS. Long‐lasting psychotomimetic consequences of repeated low‐dose amphetamine exposure in rhesus monkeys. Neuropsychopharmacology 1999; 20: 10–28
   PubMed Web of Science ®Google Scholar
• McNamara CG, Davidson ES, Schenk S. A comparison of the motor‐activating effects of acute and chronic exposure to amphetamine and methylphenidate. Pharmacology Biochemistry and Behaviour 1993; 45: 729–732
   PubMedGoogle Scholar
• Crawford CA, McDougall SA, Meier TL, Collins RJ, Watson JB. Repeated methylphenidate treatment induces behavioral sensitization and decreases protein kinase A and dopamine‐stimulated adenylyl cyclase activity in the dorsal striatum. Psychopharmacology 1998; 136: 34–43
   PubMedGoogle Scholar
• Ridley RM, Baker HF, Owen F, Cross AJ, Crow TJ. Behavioral and biochemical effects of chronic treatment with amphetamine in the vervet monkey. Neuropharmacology 1983; 22: 551–554
   PubMedGoogle Scholar
• Ellison G, Ratan R. The late stage following continuous amphetamine administration to rats is correlated with altered dopamine but not serotonin metabolism. Life Sciences 1982; 31: 771–777
   PubMedGoogle Scholar
• Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Research 1986; 396: 157–198
   PubMed Web of Science ®Google Scholar
• Yuan J, McCann U, Ricaurte G. Methylphenidate and brain dopamine toxicity. Brain Research 1997; 767: 172–175
   PubMedGoogle Scholar